home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 05/13/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn Completed Submission of All Remaining Parts of Biologics License Application ("BLA") on May 11, 2020

CytoDyn Submits Requested Datasets to FDA for Biologics License Application VANCOUVER, Washington, May 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 14...
CYDY - CytoDyn to Present at Wall Street Reporter's NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT

VANCOUVER, Washington, May 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced ...

CYDY - CytoDyn: Matching Leronlimab Up Against Other COVID-19 Therapeutics

As the worldwide death toll surpasses 250K, scientists from around the world are in a race to discover and test effective therapeutics to treat COVID-19. Researchers are either attempting to try an already approved drug used in another indication, test a pipeline candidate or discover a novel ...

CYDY - CytoDyn Clarifies Status of Biologics License Application

VANCOUVER, Washington, May 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, tod...
CYDY - Federman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws

The law firm of Federman & Sherwood has initiated an investigation into CytoDyn Inc. (OTC: CYDY) and its officers and directors, with respect to possible violations of federal securities laws. On April 27, 2020, CytoDyn, a late-stage biotechnology company, issued a press release indicatin...

CYDY - Novant Health Initiates Phase 2b/3 Trial with CytoDyn's Leronlimab for Severely and Critically Ill COVID-19 Patients

VANCOUVER, Washington and WINSTON-SALEM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic...

CYDY - CytoDyn's Answer To COVID-19

This article reviews CytoDyn's ( OTCQB:CYDY ) 5/1/2020 Next Superstock Live 58 minute promo youtube , [the YouTube] particularly as it relates to CytoDyn's evaluation of leronlimab's MOA. I will also discuss CEO Nader Pourhassan's [NP] recent stock trade which seems to have drawn such outsize...
CYDY - Manuscript Describes How CytoDyn's Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients

Manuscript Posted Online to Research Square and MedRxiv Pre-print Server VANCOUVER, Washington, May 05, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...

CYDY - "Next Super Stocks" in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman -  CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting leaders presenting at it’s NEXT SUPER STOCK investor livestream conference series that are making news this week. fuboTV (OTC: FUBO) Appoints Edgar Bron...

CYDY - CytoDyn down 9% as CEO sells stock while touting COVID-19 drug

CytoDyn ( OTCQB:CYDY -8.8% ) is under early pressure on the heels of a report from STAT's Adam Feuerstein questioning management's motives behind its aggressive promotion of leronlimab for the treatment of COVID-19 patients. More news on: CytoDyn Inc., Healthcare stocks news, Stocks on...
Previous 10 Next 10